Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantitative polymerase chain reaction of t(14;18)-positive cells in follicular lymphoma, and by immunophenotyping in small lymphocytic lymphoma. Before DLI, three patients were treated with chemo-and/or radiotherapy, and one with rituximab. Evaluable responses to pre-DLI therapy were stable disease in one and partial remission (PR) in two patients. Six patients responded to DLI (complete remission (CR) in four and PR in two). After DLI, acute graft-versus-host disease (GVHD) occurred in 3/6 patients, classified as grade 2, whereas only limited chronic GVHD was seen (n ¼ 5). The four continuous CR are lasting for median 65 þ (43-89) months. In the remaining patient, not responding to DLI, progressive disease was seen later on; chemotherapy followed by another DLI resulted in CR. In three cases, clinical responses to DLI could be substantiated by molecular or immunophenotypic analysis of lymphoma cells. We conclude that DLI is effective for treatment of indolent lymphoma relapsing after SCT. Myeloablative therapy followed by allogeneic stem cell transplantation (SCT) has emerged as a promising treatment modality for selected patients with indolent types of non-Hodgkin's lymphoma (NHL). Response rates of 50-70% and relapse percentages of about 15 have been reported in series of predominantly heavily pretreated patients.
infusion; t (14;18) Myeloablative therapy followed by allogeneic stem cell transplantation (SCT) has emerged as a promising treatment modality for selected patients with indolent types of non-Hodgkin's lymphoma (NHL). Response rates of 50-70% and relapse percentages of about 15 have been reported in series of predominantly heavily pretreated patients. [1] [2] [3] As similar conditioning regimens followed by autologous stem cell rescue result in comparable response, but higher relapse rates, 1,4,5 a graft-versus-lymphoma effect is assumed to be involved in allogeneic SCT, as already suggested over a decade ago. 6 In case of relapsed haematologic disease after allogeneic SCT, remission can still be induced by shifting the balance between patient and donor immunoreactive cells in favour of the donor, either by diminishing the patient's immunosuppressive medication, 7 or by infusion of lymphocytes derived from the original stem cell donor. [8] [9] [10] [11] [12] [13] [14] [15] Especially in relapsed chronic myeloid leukaemia after allogeneic transplantation, these donor lymphocyte infusions (DLI) are effective, whereas in relapsed acute leukaemia responses to DLI are rather disappointing.
Earlier, we described a patient with relapsed follicular NHL after allogeneic SCT, in whom the clinically observed graft-versus-lymphoma effect of DLI was substantiated by molecular analysis of circulating cells carrying the characteristic chromosomal translocation t(4;18). 16 Here, we describe seven patients treated with DLI for indolent lymphoma relapsed after allogeneic SCT. The observed responses are illustrated with available molecular and immunophenotypic data.
Patients and methods

Patients
Since 1989, in the University Medical Centers Nijmegen and Utrecht, 50 patients have been treated with myeloablative therapy and T cell-depleted allogeneic SCT for relapsed indolent lymphoma. Seven of them relapsed after SCT and received therapeutic DLI. Donors were HLAidentical siblings. Grafts had been partially depleted of T cells by counterflow centrifugation 17 or SBA/E-rozetting, 18 respectively. Characteristics of the seven patients are given in Table 1 . Clinical, laboratory, radiological, and pathological data were collected from the medical records. Chemo-and/or radiotherapy was administered prior to DLI in cases of lymphoma relapses post-SCT at localisations with potential short-term threatening complications. In the University Medical Center Nijmegen, patients (# 1-3) were treated with one DLI, consisting of median 0.5 (range 0.5-0.7) Â 10 8 CD3 þ cells/kg body weight. In the University Medical Center Utrecht, dose-escalated DLI was given to patients (# 4-7). This means that in case of failure in absence of graft-versus-host disease (GVHD) of a first DLI, consisting of 1.0 Â 10 7 CD3 þ cells/kg, a second DLI was given consisting of 1.0 Â 10 8 CD3 þ cells/kg. GVHD was staged according to literature. 19, 20 Follow-up ended on 1 July 2003.
Methods
In available bone marrow and blood samples, lymphoma cells were analysed by real-time quantitative polymerase chain reaction (PCR) of t(14;18)-positive cells in follicular NHL, 21, 22 and by immunophenotyping in small lymphocytic NHL. The sensitivity of the PCR is detecting a single lymphoma cell in 75 000 normal cells.
Results
Clinical data
Seven consecutive patients received therapeutic DLI after SCT for relapsed indolent lymphoma. After the previous SCT, neither acute GVHD Xgrade 2 nor extensive chronic GVHD occurred. Relapses were diagnosed after a median of 25 (range 12-73) months after SCT. All patients presented with relapsing lymphoma at previously involved lymph node sites. Furthermore, six patients had lymphoma involvement of the bone marrow.
Patient characteristics are shown in Table 1 . DLI was given without any pretreatment in 3/7 patients. Prior to DLI, two patients were treated with anthracyclin-containing combination chemotherapy, preceded by radiotherapy in one, to induce rapid response for complicating ischaemic colitis and osteolytic femoral lesion, respectively. Another patient responded partially to anti-CD20 (rituximab), given 4 months before DLI, for clinically rapidly progressive, but histologically still indolent lymphoma. Finally, one patient was treated with corticosteroids and cyclophosphamide prior to DLI, as the relapsed indolent NHL concurred with polyneuropathy. Response to pre-DLI therapy occurred in two patients, both achieved a partial remission (PR).
In six patients, a gradual response to DLI was seen (complete remission (CR) in four and PR in two). Three of them developed acute GVHD, classified as grade 2, and five chronic GVHD, which was limited. The four continuous CR are lasting for median 65 þ (43-89) months. In the remaining patient (#7), who did not achieve a remission nor GVHD to DLI, progressive disease was seen 7 months after DLI. Treatment with anthracyclin-containing combination chemotherapy resulted in PR, and subsequently another DLI (1.0 Â 10 8 CD3 þ cells/kg) in CR, lasting for 12 þ months, at the cost of acute GVHD grade 2 and extensive chronic GVHD. Two patients have died up to now. The first patient died 2 months after DLI of an Aspergillus fumigatus pneumonia, while receiving corticosteroids for acute GVHD grade 2. The second patient died 17 months after DLI of liver failure of unknown cause, as diagnostic procedures had been refused. Figures 1 and 2 show the results of molecular monitoring of circulating follicular lymphoma cells by real-time quantitative PCR analysis of t(14;18)-positive cells in available bone marrow and peripheral blood samples in two patients.
Molecular and immunophenotypic data
Molecular data of the first patient ( Figure 1 ) have in part been published previously. 16 She presented with a leukaemic NHL with lymphocytes of 10.2 Â 10 9 /l and 43.506 t(14;18)-positive cells/75 000 cells in the peripheral blood. While clinically a CR was seen after SCT, molecular analysis demonstrated still persistence of disease, which increased before clinical evidence of relapse. After single treatment with DLI, a complete clinical and molecular remission was achieved. Until now, this CR is lasting for 89 þ months. Only limited chronic GVHD was seen after DLI.
In the second patient (Figure 2 ), samples for molecular monitoring of disease were available since SCT. Almost complete clearing of t(14;18)-positive cells from the blood was seen after SCT, while clinically a CR was observed. The number of t(14;18)-positive cells increased at clinical relapse, 6 years after SCT. Treatment with combination chemotherapy, initiated to induce a rapid response of the relapse causing ischaemic colitis, failed. DLI resulted in a clinical and molecular CR. This CR has lasted for 43 þ months up to now. Acute GVHD grade 2 and limited chronic GVHD occurred. Figure 3 shows clinical and immunophenotypic data of a third patient, presenting with a CD5 þ CD19 þ small lymphocytic NHL. Immunophenotypic results were available since relapse after SCT. At that time in the peripheral /l. After DLI as single therapy percentages of CD5 þ CD19 þ cells of B-lymphocytes were 53 and 60 in peripheral blood and bone marrow, respectively, both decreasing to percentages in the normal range while clinically a CR was observed. Until now, this CR has lasted for 49 þ months.
In one patient with relapsed follicular NHL after SCT, t(14;18)-positive cells could be detected in the peripheral blood taken just before DLI (2960 t(14;18)-positive cells/ 75 000 cells), but unfortunately, no follow-up samples were present. In the two remaining patients with follicular NHL, pre-DLI blood samples were t(14;18) negative in one and were not available in the other.
Discussion
Here we have shown the graft-versus-lymphoma effect of infusion of lymphocytes derived from the original stem cell donor in seven consecutive patients with indolent lymphoma relapsed after allogeneic stem cell transplantation. Incidence of graft-versus-host disease after DLI is low. Clinical responses are illustrated with molecular data in two and with immunophenotypic data in one patient, demonstrating in detail the efficacy of DLI.
Treatment of patients with indolent lymphomas remains a dilemma. Initially, a wait and see policy is allowed in an asymptomatic patient. Once therapy is indicated, temporal responses are generally seen to several treatment modalities and regimens for years. To overcome the ever relapsing nature of this lymphoma, ultimately being the cause of death, intensive myeloablative treatment followed by allogeneic SCT has been initiated in selected patients, expecting that a graft-versus-lymphoma effect will exist. Yet, relapses are still occurring after allogeneic transplantation with reported relapse rates ranging from 0 to 29% 3 years after SCT for chemotherapy sensitive or resistant disease. [1] [2] [3] As shown here, indolent lymphomas that relapse after SCT still respond to DLI. The indolent lymphoma patients described here were all poor-risk patients, being relatively old at the time of SCT for relapsed disease. All reached CR after SCT. As expected, in case of relapse it occurred after a rather long period of time after SCT. Only two of three evaluable patients responded to the chemo-, radio-or anti-CD20 therapy prior to DLI, instituted for clinically threatening relapses. Six of seven patients responded to DLI, with predominantly limited GVHD. The remaining patient, without response and GVHD to DLI, achieved a PR after chemotherapy, which was converted in a CR by another DLI. The two deaths were caused by infectious disease in one patient and liver failure of unknown cause in another patient.
Real-time PCR monitoring of t(14;18)-positive cells, as shown in two follicular lymphoma patients, correlated well with the clinically observed CR to DLI, with complete clearing of lymphoma cells from the peripheral blood, as well as from the bone marrow in one patient. During clinical remission after allogeneic SCT of both patients #1 and #2, lasting for 2 and 6 years, respectively, molecular analysis was still showing circulating lymphoma cells in high and low numbers, respectively, thus corresponding with the residual disease. Both patients showed correlating molecular and clinical results late in the course of follicular NHL. On the other hand, earlier in the course of disease that is after first-line therapy, we could not find a correlation between circulating t(14;18)-positive cells and clinical disease status. 22 Immunophenotypic data in the third patient treated with DLI again correlated with clinical findings, with disappearance of CD5 þ CD19 þ clone of the peripheral blood and bone marrow in CR after DLI.
In both the University Medical Centers Nijmegen and Utrecht, allogeneic SCT for indolent lymphoma patients is being performed with a T cell-depleted graft. We will continue to do so, as relapse rates after allogeneic SCT are small despite T cell depletion, whereas morbidity and mortality due to GVHD are low. Furthermore, in cases of relapse disease after allogeneic SCT, DLI can still induce remission.
We conclude that infusion of donor lymphocytes is an effective treatment for indolent lymphoma relapsed after SCT, without severe GVHD. In this clinical setting, monitoring numbers of t(14;18)-positive cells in follicular lymphoma appeared to correlate with residual disease activity and subsequent achievement of a 'real' CR after DLI.
